Hologic (NASDAQ:HOLX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Saturday.

Other equities research analysts have also issued reports about the stock. TheStreet upgraded shares of Hologic from a “c” rating to a “b” rating in a research report on Tuesday, July 31st. Cowen reaffirmed a “buy” rating and set a $45.00 price target on shares of Hologic in a research note on Wednesday, August 1st. Bank of America lifted their price target on Hologic from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Jefferies Financial Group reaffirmed a “buy” rating and set a $50.00 price target on shares of Hologic in a research note on Wednesday, August 1st. Finally, Needham & Company LLC lifted their price target on Hologic from $43.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Ten equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Hologic has an average rating of “Hold” and an average target price of $44.47.

Shares of NASDAQ HOLX opened at $39.64 on Friday. The firm has a market cap of $10.63 billion, a price-to-earnings ratio of 19.53, a P/E/G ratio of 1.78 and a beta of 0.65. Hologic has a one year low of $35.10 and a one year high of $45.09. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.29.

Hologic (NASDAQ:HOLX) last issued its earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, topping the consensus estimate of $0.56 by $0.02. The company had revenue of $824.00 million for the quarter, compared to analyst estimates of $800.14 million. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%. analysts forecast that Hologic will post 2.24 EPS for the current year.

Large investors have recently added to or reduced their stakes in the company. D.A. Davidson & CO. acquired a new position in Hologic in the 1st quarter valued at about $242,000. State of Wisconsin Investment Board raised its stake in Hologic by 25.3% in the 1st quarter. State of Wisconsin Investment Board now owns 354,455 shares of the medical equipment provider’s stock valued at $13,242,000 after purchasing an additional 71,461 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in Hologic by 7.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 1,127,294 shares of the medical equipment provider’s stock valued at $42,116,000 after purchasing an additional 74,771 shares during the last quarter. Synovus Financial Corp acquired a new position in Hologic in the 1st quarter valued at about $164,000. Finally, Aperio Group LLC raised its stake in Hologic by 39.9% in the 1st quarter. Aperio Group LLC now owns 103,854 shares of the medical equipment provider’s stock valued at $3,880,000 after purchasing an additional 29,612 shares during the last quarter. 98.65% of the stock is owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: What is a Fiduciary?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.